MMSL 2016, 85(4):164-170 | DOI: 10.31482/mmsl.2016.028

CHARACTERISTICS OF VARICELLA ZOSTER (VZV) VIRUSReview article

Vanda Boštíková ORCID...1*, Radek Sleha ORCID...1, Miloslav Salavec2, Sylva Janovská ORCID...1, Roman Chlíbek ORCID...1, Pavel Blažek ORCID...3, Hana Střítecká ORCID...4, Vladislav Hytych5, Kamil Kuča ORCID...6,7, Irena Hanovcová ORCID...1, Renáta Šošovičková ORCID...1, Jan Smetana ORCID...1, Miroslav Špliňo ORCID...1, Jan Marek ORCID...1, Pavel Boštík ORCID...1,8
1 Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
2 Department of Dermatovenerology, Charles University Medical School and University Hospital, Hradec Kralove, Czech Republic
3 Department of Military Medical Service Organisation and Management, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
4 Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
5 Thomayer Hospital, Prague, Czech Republic
6 Faculty of Informatics and Managment, University of Hradec Kralove, Hradec Kralove, Czech Republic
7 Biomedical Research Center, University Hospital of Hradec Kralove, Hradec Kralove, Czech Republic
8 Department of Infectious Diseases, Charles University, Medical School and Faculty Hospital, Hradec Kralove, Czech Republic

The evolution of varicella zoster virus lasts more than 400 million years. While primates were the original reservoirs of the virus, subsequently VZV started to circulate in human population and humans have been the exclusive hosts for VZV for more than 45 000 years. VZV is a highly contagious and neurotropic herpetic virus a member of the herpesviridae family.Its primary infection results in typical signs of varicella (chickenpox). After that, the virus establishes lifelong latency in trigeminal and dorsal root ganglia. Endogenous viral reactivation, thought to be associated with waning VZV specific T cell mediated imunity, leads to herpes zoster (shingles), especially in older adults and immunocompromised persons (VZV is the only human herpetic virus exhibiting entirely different clinical picture).

Keywords: varicella zoster virus; herpetic viruses; DNA; vaccination; epidemiology; chickenpox; shingles

Received: December 6, 2016; Revised: December 16, 2016; Published: December 16, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boštíková, V., Sleha, R., Salavec, M., Janovská, S., Chlíbek, R., Blažek, P., ... Boštík, P. (2016). CHARACTERISTICS OF VARICELLA ZOSTER (VZV) VIRUS. MMSL, 85(4), 164-170. doi: 10.31482/mmsl.2016.028
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arvin, A. M. Varicella-zoster virus: overview and clinical manifestations. Semin. Dermatol. 1996, 15, 4-7. Go to PubMed...
    2. Loparev, V. N., A. Gonzalez, M. Deleon-Carnes, G. Tipples, H. Fickenscher, E. Torfason, D. S.Schmid. Global identification of three major genotypes of VZV: longitudinal clustering and strategies for genotyping. J. Virol. 2004, 78, 8349-8358. Go to original source... Go to PubMed...
    3. Arvin A. M., A. A.Gershon. Varicella zoster virus. The Pitt Bldg., Cambridge, UK. 2007. Go to original source...
    4. Quinlivan, M., J. Breuer. Molecular and therapeutic aspects of VZV infections. Expert. Rev. Mol. Med. 2005, 7(15), 1-24. Go to original source... Go to PubMed...
    5. Arvin, A. M. 1999. Chickenpox. Contrib. Microbiol. 3: 6-110. Go to original source... Go to PubMed...
    6. Ganna, J.W. 2002. VZV: atypical presentations and unusual complications. J. Infect. Dis. 2002, 186, S91-S98.
    7. Shields K. E., K. Galil, J. Seward, R. G. Sharrar, J. F. Cordero, E. Slater. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet Gynecol. 2001, 98(1), 14-19. Go to PubMed...
    8. Cohen A, P. Maschopoulos, R. E. Stiehm, G. Koren. Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin. CMAJ. 2001, 183, 204-208.
    9. Breuer J. 2010. VZV molecular epidemiology. Curr Top Microbiol Immunol. 2010, 342, 15-42. Go to original source... Go to PubMed...
    10. Barrett-Muir, W., Scott, F. T., Aaby, P. J., John, P., Matondo, Q. L., Chaudhry, M., Siqueira, A., Poulsen, K., Yaminishi, Y. and Breuer, J. Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J. Med. Virol. 2003, 70 Suppl 1, S42-7. Go to original source... Go to PubMed...
    11. Loparev, V. N., E. Rubtcova, J. Seward, D. S. Schmid, M. Levin. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J. Infect. Dis. 2007, 195(4), 502-510. Go to original source... Go to PubMed...
    12. Loparev, V. N., T. Argaw, P. Krause, M. Takayma, D. S.Schmid. Improved identification and differentiation of VZV wild-type strains and an attenuated varicella vaccine strain using a VZV ORF 62-based PCR. J. Clin. Microbiol. 2000, 38, 3156-160. Go to original source... Go to PubMed...
    13. Saurbrei, A., E. Rubtcova, P. Wutzler. Genetic profile of an Oka vaccine variant isolated from an infant with zoster. J. Clin. Microbiol. 2004, 42, 5602-5608. Go to original source... Go to PubMed...
    14. Gershon A. A. The current status of live attenuated varicella vaccine. Arch. Virol. Suppl. 2001, 17, 1-6. Go to original source... Go to PubMed...
    15. Watson B., E. Rohstein, H. Bernstein, A. Arbeter, A. Arvin, S. Chartrand, D. Clements, M. L. Kumar, K. Reisinger, M. Blatter. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995, 172(1), 217-9. Go to original source... Go to PubMed...
    16. Kuter B., H. Matthews, H. Shinefield, S. Black, P. Dennehy, B. Watson, K. Reisinger, L. L. Kim, J. Hartyel, I. Chan. 2004. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.PIDJ. 2004, 23(2), 132-137.
    17. Takahashi M., Asano Y., Kamiya H., Baba K., Ozako T., Otsuka T., Yamanishi K. Development of varicella vaccine. J. of Infect. Dis. 2008, 197, 41-44. Go to original source... Go to PubMed...

    Return to the content